Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is CRISPR safe? Genome editing gets its first FDA scrutiny

Advisers to the US regulatory agency will examine the safety profile of a CRISPR-based treatment for sickle-cell disease.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

A therapy based on the CRISPR–Cas9 genome-editing system could become the first of its kind to gain approval from the US Food and Drug Administration. But the treatment — designed to alleviate a painful blood condition — must first face intense scrutiny by the agency and its advisers.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 623, 234-235 (2023)

doi: https://doi.org/10.1038/d41586-023-03317-7

Updates & Corrections

  • Correction 31 October 2023: An earlier version of this article incorrectly stated the location of bluebird bio. It also incorrectly stated the number of clinical trial participants who provided data about vaso-occlusive crises at nine months and the number who had not had a crisis.

  • Correction 07 November 2023: One sentence in an earlier version of this article misspelt Tosin Ola’s surname.

References

  1. Goyal, S. et al. N. Engl. J. Med. 386, 138–147 (2022).

    Article  PubMed  Google Scholar 

  2. Brunson, A. et al. Blood 130, 1597–1599 (2017).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links